Condition category
Eye Diseases
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
The Ocutec family of contact lenses are designed for the correction of near and far sightedness. Hyperopia, or farsightedness, is a common vision problem, affecting about a quarter of the population. People with hyperopia can see distant objects very well, but have difficulty focusing on objects that are up close. Farsighted people sometimes have headaches or eyestrain and may squint or feel fatigued when performing work at close range. Near sightedness, or myopia, is the most common condition of the eye, and it has become more common in recent years. If you are near sighted, you typically will have difficulty reading road signs and seeing distant objects clearly, but will be able to see well for close-up tasks such as reading and computer use. Other signs and symptoms of myopia include squinting, eyestrain and headaches. Feeling fatigued when driving or playing sports also can be a symptom of uncorrected near sightedness. Ocutec’s lens is based on a new material that is designed to improve the quality of the contact lens wearing experience and provide a healthier lens. The aim of this study is to compare Ocutec’s lens with an established brand, assessing the comfort and fit of the lenses.

Who can participate?
Volunteers aged 18 or over who wear glasses or contact lenses.

What does the study involve?
Each participant wears an Ocutec lens in one eye and an established brand of lens in the other eye for a period of 8 hours and is assessed at three different times throughout the day: on inserting the lens, after 30 minutes wear and then again after 8 hours wear. All volunteers undergo the same assessments, testing the ease of handling of the lens, comfort, vision and the fit of the lens.

What are the possible benefits and risks of participating?
There may not be any direct benefits to the volunteers in this study, but the study may contribute to scientific research that could be used to develop new products. This is low risk study, based on international standards. The risk to volunteers is further reduced as the lenses are only on the eye for 8 hours and will be monitored closely by the investigator. Complications that may occur during the wear of the lens include discomfort, dryness, aching or itchy eyes, and blurred vision. There is also a small risk of infection, although contact lens related infections are very rare the possibility does still exist.

Where is the study run from?
Visioncare Research, Craven House, Surrey, UK.

When is the study starting and how long is it expected to run for?
November 2015

Who is funding the study?
Ocutec Ltd (UK)

Who is the main contact?
Dr Graeme Young

Trial website

Contact information



Primary contact

Ms Tamera Smith


Contact details

Ocutec Ltd
3 Clark Way
United Kingdom



Additional contact

Dr Roderick Bowers


Contact details

3 Clark Way
ML4 3nx
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Ocutec daily disposable contact lens comfort evaluation: a randomised double-masked contralateral study


Study hypothesis

To assess the clinical performance of PEG and PEG silicone spherical soft lenses in comparison with a control soft contact lens.

Ethics approval

West of Scotland Research Ethics Service, 18/12/2015, ref: 15/WS/0244

Study design

One-day randomised double-masked contralateral study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Please see additional files


Myopia and hyperopia


Each subject will wear a test lens in one eye and a control lens in the other for a period of 8 hours and will be assessed at three different time-points throughout the day: on insertion, after 30 minutes wear and then again at exit after 8 hours wear.

Subjective assessments: ease of handle-ability on insertion, monocular comfort on insertion.
Lens fit assessment: centration, corneal coverage, post blink movement, version lag, edge tightness, tightness on push up, diameter acceptance, overall fit acceptance, overall fit preference.
Lens surface assessment: wettability, non-invasive break-up time, pre-lens tear film quality, front surface deposits, surface preference.
Slit lamp assessment: bulbar conjunctival hyperaemia, limbal hyperaemia, tarsal hyperaemia.
Vision: monocular high and low contrast-distance visual acuity, spherical over-refraction, monocular high and low contrast VAs with over-refraction

Intervention type



Drug names

Primary outcome measure

1. Overall comfort at the 8 hour visit
2. High contrast visual acuity with over-refraction at the 8 hour visit
3. Non-invasive break up time at the 8 hour visit
4. Lens wettability at the 8 hour visit
5. Overall fit acceptance at the 8 hour visit

All the outcome measure will be assesses using standard optometry equipment and metrology and patient interviews and observation.

Secondary outcome measures

1. Bulbar hyperaemia at the 8 hour visit
2. Corneal staining at the 8 hour visit

All the outcome measure will be assesses using standard optometry equipment and metrology and patient interviews and observation.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Be at least 18 years old and full legal capacity to volunteer
2. Read, understand and sign written statement of informed consent
3. Appears able and willing to follow instructions and maintain the appointment schedule
4. Existing soft contact lens wearer (at least 4 weeks daily wear prior to study)
5. Require a visual correction in both eyes (monovision allowed but no monofit)
6. Have a spherical contact lens requirement in the range of -1.00 to -4.00 DS
7. Have no greater than 1.00 DS difference in contact lens spherical requirements between eyes
8. Have astigmatism <1.25DC in both eyes
9. Monocular distance visual acuity correctable to 6/9 (20/40) or better in each eye best sphero-cylindrical refraction
10. Have normal eyes with no evidence of any ocular abnormality or disease. For the purpose of the study a normal eye is defined as having one of these:
10.1. Clear central cornea
10.2. No anterior segment disorder
10.3. No clinically significant slit lamp findings (corneal oedema, staining, central scarring, infiltrates, active neovascularisation)
10.4. No other active ocular disease or recent surgery

Participant type

Healthy volunteer

Age group




Target number of participants


Participant exclusion criteria

1. Any systematic disease affecting ocular health
2. Any systemic or topical medications that will in the investigators opinion affect ocular physiology or contact lens performance
3. Have severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of the contact lenses
4. Has persistent, clinically significant corneal or conjuctival staining using fluorescein dye (> Grade 3)
5. Is aphakic
6. Has undergone corneal refractive surgery
7. Is participating in any other type of eye-related clinical or research study
8. Pregnancy, lactating or planning a pregnancy at the time of enrolment

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Visioncare Research
Craven House West Street
United Kingdom

Sponsor information


Ocutec Ltd (UK)

Sponsor details

3 Clark Way
United Kingdom

Sponsor type

Research organisation



Funder type


Funder name

Ocutec Ltd (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

No publications expected

Intention to publish date

Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

01/06/2018: Investigator has confirmed that no results have been published or are planned to be published. 31/05/2018: No publications found, verifying study status with principal investigator. 13/04/2016: Participant information sheet uploaded. 24/03/2016: Ethics approval information added.